# OPIOIDS & SOONERCARE

Kaitlyn Wood, MHA

Research Analyst, Pharmacy Department




#### AGENDA

- Opioid Use in Oklahoma.
- Opioid Initiatives.
  - MAT prescriptions.
  - Prescribing guideline page.
- Prescriber Reminders.
  - Lock-in program.
  - Check the PMP.

# OPIOID USE IN OKLAHOMA

### **OKLAHOMA STATISTICS**

- In 2017, there were 388 overdose deaths involving opioids.
  - 14.6 deaths per 100,000 persons.
- Neonatal Opioid Withdrawal Syndrome has increased to 8.0 per 1000 hospital births in 2014 from 1.5 per 1000 in 2004.



Source: <u>https://www.cdc.gov/drugoverdose/data/prescribing.html</u> . Accessed: August 19, 2019

### MEDICAID PATIENTS HIGH RISK

- Research shows inappropriate prescribing practices are high among Medicaid patients when compared to privately insured.
- In a 2010 study, 40% of Medicaid enrollees with prescriptions for pain relievers had at least one indicator of potentially inappropriate use of prescribing.



# OHCA RESPONSE

# MORPHINE MILLIGRAM EQUIVALENT

- Morphine is considered the gold standard for the treatment of pain and is used as the basis for comparison via morphine milligram equivalent.
- The MME provides a conversion factor for one opioid to another and gives a standard for comparison.
- The CDC encourages caution for doses exceeding 50 MME per day.

#### MME CHANGES

- In January 2019, OHCA began incorporating MME into the claims processing system.
- Overlapping opioid claims are totaled to include a member's aggregate MME per day.
- The cutoff is 90 MME per day (effective October 2019).


#### **MME DASHBOARD**

#### **Dashboard Summary**

In February 2020, there were 10,934 members with an OHCA claim for opioids. This is down • 1256 (10%) from the February 2019 count of 12,190.

In February 2020, the Avg. Claim MME per day was 37. This is down + 3 from February 2019 count of 40. In February 2020, the Avg. Cumulative MME per day was 40. This is down + 6 from February 2019 count of 45.

So far this year, there have been 214 total overdoses. This is down + 1393 from the 2019 count of 1,607.





#### 9 | OKLAHOMA HEALTH CARE AUTHORITY

### MEDICATION ASSISTED TREATMENT

- In an effort to combat prescription drug abuse, OHCA is working to reduce barriers related to substance use treatment:
  - Prior authorization requirement on certain products were removed on July 31, 2019.
  - Prescribers must have an active DEAX number on file with OHCA to prescribe MAT products.
  - Continued PA requirements can be checked at: <u>http://okhca.org/MAT</u>.

#### MAT PRODUCTS


No Prior Authorization Required	Prior Authorization Required
<ul> <li>Suboxone<sup>®</sup> (buprenorphine/naloxone SL films)(BRAND</li> </ul>	<ul> <li>Bunavail<sup>®</sup> (buprenorphine/naloxone buccal films)</li> </ul>
PREFERRED)	<ul> <li>Zubsolv<sup>®</sup> (buprenorphine/naloxone SL tablets)</li> </ul>
<ul> <li>buprenorphine/naloxone SL tablets (Generic ONLY)</li> </ul>	<ul> <li>buprenorphine SL tablets (Subutex<sup>®</sup>)</li> </ul>
<ul> <li>Vivitrol<sup>®</sup> (naltrexone injection)</li> </ul>	<ul> <li>Probuphine<sup>®</sup> (buprenorphine implant)</li> </ul>
	<ul> <li>Lucemyra™ (lofexidine)</li> </ul>
	<ul> <li>Sublocade<sup>™</sup> (buprenorphine ER injection)</li> </ul>
	<ul> <li>buprenorphine/naloxone SL films (generic)</li> </ul>

SL = sublingual; PA = prior authorization; ER = extended-release

#### MAT AND PROVIDERS

- To ensure your DEAX is on file, email prescriber information to: providerenrollment@okhca.org.
- For more information on obtaining a waiver and DEAX number, visit: <u>https://www.samhsa.gov/medication-assisted-</u> <u>treatment/buprenorphine-waiver-management/qualify-for-</u> <u>practitioner-waiver</u>.

### MAT HANDOUT



13 | OKLAHOMA HEALTH CARE AUTHORITY

#### LOCK-IN PROGRAM


- SoonerCare pharmacy-administered program.
- Locks a member into one pharmacy AND one prescriber.
  - Pharmacy claims will deny if not from designated providers.
  - Multiple medications monitored.

#### LOCK-IN PROGRAM REFERRAL

- Members are referred anonymously via the pharmacy lock-in form (PHARM-16). FAX 866-802-4384 or call the Pharmacy Lock-in Program at 800-522-0114, Option 4.
- Any health care provider, emergency department, pharmacy, case worker or ancillary staff that may be concerned about a member with substance abuse issues.
- Upon inclusion into the Patient Review and Restriction Program, members are locked in for a period of two years, with monthly review and yearly re-evaluation.

### OPIOID PRESCRIBING GUIDELINES WEBPAGE

- <u>www.okhca.org/opg</u>.
- Resources and Handouts.
- Pain Management Toolkit.



# PRESCRIBER REMINDERS

# PRESCRIPTION DRUG MONITORING PROGRAM (PDMP)

- The prescription monitoring program is a proactive tool that assists medical professionals in making informed decisions about a patient's prior drug use history.
- Prescribers are required to check PDMP every time prior to prescribing opioids or MAT drugs.
- Medical professionals can login into the PDMP by visiting: Oklahoma.pmpaware.net/login.


#### PDMP EXAMPLE

PMP		Oklahoma PMP Aware Bureau of Narcotics For Assistance Call, (855) 965-4767
Report Prepared: 04/03/2019	Investigative Patient Report	Date Range: 10/01/2018 - 12/31/2018
Investigation Type: Case Number: Primary Drug Category: Drug Product Name: Case Notes: Agency: Contact: Buri Beasley Contact: State Medicaid Program Phone: 4055227103 Email: Buri Beasley@ohca.org		

DOB	Gender:	Patient Addre	ess One	
		Linked Recor	ds	
Name	DOB	ID	Gender	Address
Cheryl Johnson		1	1	
Cheryl Jones		2		
Cherri Johnson		3		
Cheryl Jones Johnson		4		

#### **Report Criteria**

First Name:	Last Name:	DOB: Rx D	ate From: 2018-10-01, Rx Date To: 2018-12-31			
			Summary			
Summary			Opioids* (excluding buprenorphine)		Buprenorphine*	
Total Prescrip	otions	11	Current Qty	0.0	Current Qty	0.0
Total Private	Pay	1	Current MME/day	0.0	Current mg/day	0.0
Total Prescrit	pers	4	30 Day Avg MME/day	0.0	30 Day Avg mg/day	0.0
Total Pharma	icies	4				



\*Per CDC guidance, the MME conversion factors prescribed or provided as part of medication-assisted treatment for opioid use disorder should not be used to benchmark against dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. mg = dose in milligrams.<br/>dors. The MME graph is only displayed when a request is made by Fill Date range.

	Prescriptions											
Filled	٠	ID	Written	Drug	QTY	Days	Prescriber	Rx #	Pharmacy	Refills	Daily Dose	Pymt Type
12/28/2018		3	12/28/2018	ZOLPIDEM TARTRATE 10 MG TABLET	30.0	30	Jill Smith	311896	CVS	0		Private Pay
12/28/2018		3	12/28/2018	ALPRAZOLAM 2 MG TABLET	60.0	30	Jill Smith	311897	Express RX	0		Comm Ins
12/07/2018		1	12/07/2018	ACETAMINOPHEN-COD #3 TABLET	60.0	30	Ryan Smith	189620	CVS	0	9.0 MME	Medicaid
12/01/2018		2	11/28/2018	ZOLPIDEM TARTRATE 10 MG TABLET	30.0	30	Cooper Wordsmith	449440	Walmart	0		Medicaid
12/01/2018		2	11/28/2018	ALPRAZOLAM 2 MG TABLET	60.0	30	Ryan Smith	449441	Ritescript	0		Medicaid
11/01/2018		2	11/01/2018	ALPRAZOLAM 2 MG TABLET	60.0	30	Samantha Stewart	448487	Walmart	0		Medicaid

#### PDMP EXAMPLE



Report Prepared: 04/03/2019

Investigative Patient Report

(855) 965-4767 Date Range: 10/01/2018 – 12/31/2018

Oklahoma PMP Aware

Bureau of Narcotics For Assistance Call,

Investigation Type: Case Number: Primary Drug Category: Drug Product Name: Case Notes: Agency: Contact: Burl Beasley Role: State Medicaid Program Phone: 4055227103 Email: burl.beasley@okhca.org


Gende	r:t	Patient Addre	ss One	
	1615	Linked Recor	ds	
DOB		ID	Gender	Address
	1		1	
	2			
	3		1	
	4			
	-	DOB 1	Linked Record	DOB     ID     Gender       1     1     1

#### **Report Criteria**

First Name:	Last Name:	DOB:	Rx Da	ate From: 2018-10-01, Rx Date To: 2018-12-31			
				Summary			
Summary			$\sim$	Opioids* (excluding buprenorphine)		Buprenorphine*	
Total Prescrip	ptions		11	Current Qty	0.0	Current Qty	0.0
Total Private	Pay		1	Current MME/day	0.0	Current mg/day	0.0
Total Prescrit	bers		4	30 Day Avg MME/day	0.0	30 Day Avg mg/day	0.0
Total Pharma	icies		4				

#### PDMP EXAMPLE

#### Morphine MgEq/day



\*Per CDC guidance, the MME conversion factors prescribed or provided as part of medication-assisted treatment for opioid use disorder should not be used to benchmark against dosage thresholds meant for opioids prescribed for pain. Buprenorphine products have no agreed upon morphine equivalency, and as partial opioid agonists, are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids. MME = morphine milligram equivalents. mg = dose in milligrams.<br/>br><br/>The MME graph is only displayed when a request is made by Fill Date range.

	Prescriptions										
Filled 👻	ID	Written	Drug	QTY	Days	Prescriber	Rx #	Pharmacy	Refills	Daily Dose	Pymt Type
12/28/2018	3	12/28/2018	ZOLPIDEM TARTRATE 10 MG TABLET	30.0	30	Jill Smith	311896	CVS	0		Private Pay
12/28/2018	3	12/28/2018	ALPRAZOLAM 2 MG TABLET	0.00	30	Jill Smith	311897	Express RX	0		Comm Ins
12/07/2018	1	12/07/2018	ACETAMINOPHEN-COD #3 TABLET	60.0	30	Ryan Smith	189620	CVS	0	9.0 MME	Medicaid
12/01/2018	2	11/28/2018	ZOLPIDEM TARTRATE 10 MG TABLET	30.0	30	Cooper Wordsmith	449440	Walmart	0	1	Medicaid
12/01/2018	2	11/28/2018	ALPRAZOLAM 2 MG TABLET	60.0	30	Ryan Smith	449441	Ritescript	0		Medicaid
11/01/2018	2	11/01/2018	ALPRAZOLAM 2 MG TABLET	0.00	30	Samantha Stewart	448487	Walmart	0		Medicaid

## E-PRESCRIBING OF CONTROLLED SUBSTANCES

- E-prescribing of CII and CIII-V is permitted by Oklahoma state law and is now mandatory as of January 2020.
- E-prescribing helps reduce Rx drug abuse and creates tamper-proof transactions, which result in a reduction of diversion and fraud.
- If you have questions regarding e-prescribing, please contact OBNDD (<u>https://www.ok.gov/obndd</u>).

### NALOXONE COMPANION

- Law passed in 2013 to allow use of naloxone outside a medical setting.
- Naloxone should be prescribed for patients taking MAT medications or patients that are high risk for opioid overdose.
  - Receive rotating opioid medication regimens.
  - Have been discharged from emergency medical care following opioid poisoning or intoxication.
  - Take certain extended-release or long-acting opioid medications.
  - Are completing mandatory opioid detoxification or abstinence programs.

CONTACTING PHARMACY DEPARTMENT

#### PHARMACY HELPDESK

- Phone number: (800)-522-0114, option 4.
- Hours:
  - Monday-Friday: 8 a.m. to 7 p.m.
  - Saturday: 9 a.m. to 5 p.m.
  - Sunday: 11 a.m. to 5 p.m.

#### PHARMACY DEPARTMENT

If you have a question or need assistance, you can always email us at <a href="mailto:pharmacy@okhca.org">pharmacy@okhca.org</a>.



Oklahoma Health Management Program: Practice Facilitation

Trevor Neering, RN, BSN Karen Johnston, RN, BSN, MS





- 2008 The Oklahoma Health Care Authority contracted Telligen as the administrator of the Health Management Program
- Identify high-risk and at-risk
   SoonerCare Choice members
- Quality improvement



#### **PRINCIPLES OF HEALTH COACHING**



- Self-management support
- Medication adherence
- Coordinated care across the care continuum
- Liaison with family, healthcare providers and community resources







- Screen newly enrolled SoonerCare Choice population
- Reduce member's social determinants of health
- Assess behavioral health needs

**Resource Navigators:** 

- Outreach
- Connect
- Collaborate

#### **Practice Facilitation**



- Practice assessment.
- Process improvement.
- Evidence-based care support.
- Quality improvement.
- Provider education.





#### **Practice Facilitation Measures**

- Asthma
- Behavioral Health
- Chronic Obstructive Pulmonary Disease
- Chronic Pain
- Coronary Artery Disease
- Diabetes
- Hypertension
- Pediatric Weight Assessment and Counseling for Nutrition and Physical Activity
- Tobacco Cessation





- Treatment protocols
- Evidence-based guidelines
- Practice tools
- Process recommendations
- Research articles



- Breaks down the recommendations into specific visit components
- Streamlines the guideline components into concrete tasks
- The treatment protocols are given to clinics as a pocket card to use as a to-do list and aid in following pain management recommendations.



- These sections of the tool kit are used to provide clinics with up-to-date recommendations
  - CDC
  - Oklahoma
  - State Board licensure requirements for MD's and DO's
  - Synopsis of Senate Bills 1446 and 848 requirements





- This section includes a variety of assessment tools to help providers and staff evaluate their members risk of substance use disorder compared to the treatment benefit
  - Pain Assessment Documentation Tool –covers assessment of the 4 A's- analgesia, activity, adverse
    effects and aberrant behavior
  - Pain Assessment
  - Functional Assessment
  - Substance Use Risk Assessment
  - Behavioral Health Screening
  - Patient care plans



- Patient/Provider Agreement and informed consent templates
- Prescribing Monitoring Program information
- Non-Opioid Options- pharmacologic and non-pharmacologic
- Urine drug screenings and tests
- Naloxone kit information
- Additional patient and provider handouts to supplement ongoing education
- Tapering information

#### **HMP Outcomes**



- 90% of providers credit practice facilitation with having a positive impact on enrolled patients
- High-risk patients spent 48% fewer days in the hospital and had 28% fewer ER visits
- 83% of providers reported making changes to how they care for patients with chronic pain and opioid utilization
- 15% decrease in the number of patients receiving opioid prescriptions.



Trevor Neering, RN, BSN Manager, Practice Facilitation tneering@telligen.com

(405) 810-3206

#### **Contacting Telligen**





